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Immunotherapy has increased overall survival of metastatic cancer patients, and cancer
antigens are promising vaccine targets. To fulfill the promise, appropriate tailoring of
the vaccine formulations to mount in vivo cytotoxic T cell (CTL) responses toward
co-delivered cancer antigens is essential. Previous development of therapeutic cancer
vaccines has largely been based on studies in mice, and the majority of these candidate
vaccines failed to induce therapeutic responses in the subsequent human clinical trials.
Given that antigen dose and vaccine volume in pigs are translatable to humans and
the porcine immunome is closer related to the human counterpart, we here introduce
pigs as a supplementary large animal model for human cancer vaccine development.
IDO and RhoC, both important in human cancer development and progression, were
used as vaccine targets and 12 pigs were immunized with overlapping 20mer peptides
spanning the entire porcine IDO and RhoC sequences formulated in CTL-inducing
adjuvants: CAF09, CASAC, Montanide ISA 51VG, or PBS. Taking advantage of
recombinant swine MHC class I molecules (SLAs), the peptide-SLA complex stability
was measured for 198 IDO- or RhoC-derived 9-11mer peptides predicted to bind to
SLA-1∗04:01, −1∗07:02, −2∗04:01, −2∗05:02, and/or −3∗04:01. This identified 89
stable (t ≥ 0.5 h) peptide-SLA complexes. By IFN-½ γ release in PBMC cultures we
monitored the vaccine-induced peptide-specific CTL responses, and found responses to
both IDO- and RhoC-derived peptides across all groups with no adjuvant being superior.
These findings support the further use of pigs as a large animal model for vaccine
development against human cancer.
Keywords: immune therapy, cancer vaccines, cytotoxic T cells, animal model, peptide-MHC stability, adjuvants,
immunologic
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Introduction
Therapeutic anti-cancer vaccines are expected to be important in
the future immunotherapeutic treatment of cancer, either alone
or in combinationwith, e.g., administration of drugs targeting the
checkpoint inhibitors cytotoxic T-lymphocyte-associated protein
4 (CTLA-4) and programmed cell death 1 (PD-1) (Hodi et al.,
2010; Brahmer et al., 2012; Topalian et al., 2012; Hamid et al.,
2013; Wolchok et al., 2013). Previously, vaccines have mainly
been comprised of full proteins; however especially in terms
of safety, peptide-based vaccines are preferable, as reviewed
in Purcell et al. (2007). Many cancer-associated targets have
been described (Cheever et al., 2009; Andersen et al., 2012),
and peptide vaccinations have previously generated significant
immune responses, although these only rarely correlated with
the clinical outcome (Dalgleish and Whelan, 2006; Becker et al.,
2012; Inderberg-Suso et al., 2012). One limitation to peptide
vaccination is that peptides in general generate weaker responses
in vivo as compared to full protein, and the immunogenicity
of peptides alone is not sufficient to generate a strong immune
response; therefore adjuvant systems are included to enhance
such response in order to increase the likelihood of a clinical
effect. Numerous adjuvant systems have proved the ability to
strongly stimulate the unspecific immune system in a cancer
setting (Butterfield, 2015) hence supporting the need for studies
identifying optimal Th1-inducing adjuvants in combination with
cancer antigens.
Various mice models are currently the golden standard for
early pre-clinical studies, even though important differences
in terms of immunology and physiology between mice and
humans exist. It is now well established that “mice lie” and
recent studies have shown the pig immunome to be much more
similar to the human counterpart (Dawson et al., 2013; Seok
et al., 2013); pigs must therefore be considered a highly relevant
supplementary model when studying human immune activation.
Furthermore, the difference in body size and metabolism makes
studies on the dose effect of adjuvants and peptides impossible
to extrapolate from mice studies to human vaccine formulation.
Relating specifically to cancer, six genetic defects are required
for converting both normal porcine and human cells to their
cancerous counterparts (Hahn et al., 1999; Adam et al., 2007),
while only two mutations are required to convert a mouse cell
(Rangarajan et al., 2004). Over the last decade the toolbox of
swine immunological reagents has expanded considerably, which
contributes further to the usefulness of pigs as a relevant model
for human diseases (Meurens et al., 2012). In this study we
introduce outbred pigs as a large animal model for human cancer
vaccine development.
The immune response to cancer is complex and responses
can either be in favor or disfavor of cancer development
Abbreviations: CAF09, Cationic Adjuvant Formulation 09; CASAC, Combined
Adjuvant for Synergistic Activation of Cellular Immunity; CTL, Cytotoxic T cell;
IDO, Indoleamine 2,3-dioxygenase; ISA 51VG, Montanide ISA 51VG; MHC,
Major Histocompatibility Complex; PBS, Phosphate Buffered Saline; PBMC,
Peripheral Blood Mononuclear Cell; RhoC, Ras homolog gene family member
C; SEB, Staphylococcal Enterotoxin B; SLA, Swine Leukocyte Antigen; SPA,
Scintillation Proximity Assay.
and progression. Major players in the anti-cancer immune
response are the CD8+ cytotoxic T lymphocytes (CTLs),
which specifically recognize peptides derived from cancer-
specific or over-expressed proteins when presented by the
Major Histocompatibility Complex (MHC) class I molecules
on the surface of the transformed cells or cross-presented by
dendritic cells. Mounting strong and effective CTL responses
against such peptide-MHC complexes is thus a goal of
vaccine development against cancer. Previous work has shown
indoleamine 2,3-dioxygenase (IDO) and Ras homolog gene
family member C (RhoC) to be promising antigen targets for
inclusion in vaccines against multiple cancer forms (Wenandy
et al., 2008; Sørensen et al., 2009). To investigate whether
it is possible to mount immune responses toward the above
mentioned cancer antigens, we immunized 12 healthy outbred
pigs holding the swine leukocyte antigen (SLA)-1∗04:01,
SLA-3∗04:01, SLA-1∗07:02, and/or SLA-2∗05:02 MHC class I
alleles with 20mer overlapping peptides spanning the entire
sequence of IDO and RhoC. The pigs were divided in four
adjuvant groups receiving the 20mer peptide library formulated
in either poly(I:C) decorated dimethyldioctadecylammonium
(DDA)/monomycoloyl glycerol (MMG) cationic liposomes
referred to as the cationic adjuvant formulation (CAF)09
(Korsholm et al., 2014), a porcine/human modification of the
combined adjuvant for synergistic activation of cellular immunity
(CASAC) containing CpG,monophosphoryl lipid A (MPL), IFN-
γ, CD40 ligand (CD40L), and CD40L enhancer in an oil/water
formulation (Wells et al., 2008), Montanide ISA 51VG water/oil
(Iversen et al., 2014) (hereafter referred to as ISA 51VG) or
phosphate buffered saline (PBS). These adjuvants were chosen
based on their previous ability to mount CTL responses in
mouse and/or man. CAF09 has shown promising results in a
mouse tumor model, where it generated responses to multiple
antigens in parallel (Korsholm et al., 2014) and has previously
been used several times in pigs (data not published). CASAC has
shown very promising results in mice, where it generated high
numbers of antigen-specific CD8+ T cells (Wells et al., 2008).
Among numerous human cancer studies, ISA 51VG has together
with a short IDO-derived peptide been shown to induce clinical
responses in human metastatic lung cancer patients (Iversen
et al., 2014) and has been used in various other clinical trials for
cancer treatment (Tsuji et al., 2013; Lennerz et al., 2014).
In order to compare the vaccine-induced antigen-specific
CD8+ CTL response toward IDO and RhoC between the
adjuvant groups, we predicted 198 9-11mer ligands by use of
the NetMHCcons prediction server (Karosiene et al., 2012) in
combination with the Position Scanning Combinatorial Peptide
Library (PSCPL)method (as exemplified in Pedersen et al., 2011).
Out of these, a total of 89 stable peptide-MHC complexes were
subsequently identified using in vitro stability measurements.
Pigs were blood sampled at various time points before and
after immunizations and the IFN-γ responses following∼70 h of
peripheral blood mononuclear cell (PBMC)-peptide co-culture
suggested generation of CTL responses to cancer antigens
following peptide immunization. All adjuvants were capable of
generating some CTL responses although none of the adjuvants
was found to be superior. Taken together this first vaccine
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trial supports the use of pigs as a large animal model for
human anti-cancer vaccine development. Stronger and more
consistent responses are, however, warranted indicating the
relevance of further studies on adjuvant and peptide dose,
number of immunizations and more detailed characterization of
the immunological response profile.
Materials and Methods
Animals
Outbred Danish Landrace/Yorkshire/Duroc pigs were obtained
from a Danish production farm (Askelygaard, Roskilde,
Denmark). Upon arrival to the National Veterinary Institute, the
pigs were housed in groups of six animals using straw as bedding
material with water freely available and food supplied once a
day. No additional environmental enrichment was provided.
All procedures of animal handling and experimentation were
internally and externally approved by the institutional committee
and the Danish Animal Experiments’ Inspectorate, respectively.
Blood Sampling
Blood samples from pigs were collected at day −35, −9, −2, 12,
33, 40, and day 54. The PBMCs were isolated using Lymphoprep
gradient separation in SepMate tubes (both from Stemcell
Technologies, Grenoble, France) from blood samples obtained at
day −2, 12, 33, 40, and 54 and used directly in the IFN-γ release
assay.
SLA-typing of Candidate Pigs
Five weeks old, non-sex matched pigs were
blood sampled and SLA-typed prior to purchase.
Sanger sequencing based SLA-typing: Genomic DNA was
extracted from blood samples obtained at day -35 using
DNeasy R© Blood & Tissue Kit (Qiagen, Cat. No. 69504)
according to the manufacturer’s instructions. PCR with sequence
specific primers and subsequent sequencing of the positive
amplicons (by Eurofins, Ebersberg, Germany) allowed for
detection of the alleles SLA-1∗04:01, SLA-1∗07:02, SLA-2∗04:01,
SLA-2∗05:02, and SLA-3∗04:01 as previously described (Pedersen
et al., 2014b).
NGS-based SLA-typing and Expression Analysis: To confirm
the presence of the SLA class I genes found by the previously
described SLA-typing, we used next generation sequencing of
PCR amplicons spanning exon 2 and 3 of SLA class I genes,
which also allowed for expression analysis of the transcripts.
RNA from blood samples obtained at day -9 was purified
using PAXgene Blood RNA Kit (PreAnalytiX, Cat. No. 762174)
according to the manufacturer’s instructions. After enzymatic
digestion of genomic DNA, the RNA was transcribed into cDNA
using the QuantiTect R© Reverse Transcription Kit (Qiagen,
Cat.No.205311). The cDNA was used as a template in a PCR
with barcoded primers designed in conserved areas of the exon
2 and 3 of all known SLA class I genes. After sequencing on the
MiSeq™ 250PE platform (The National High-throughput DNA
Sequencing Centre, University of Copenhagen, Denmark) the
sequences were de-multiplexed, pair mate joined, quality checked
and sorted into clusters showing the expression levels of each
allele (Ilsøe et al., manuscript in preparation). This was followed
by alignment against a library containing all previously described
SLA class I alleles to determine the allele identity.
20mer Overlapping Peptide Library for
Immunization
Fifty-nine 20mer peptides with 10mer overlap covering the entire
IDO and RhoC amino acid (aa) sequence were purchased from
Genscript (New Jersey, U.S) or Pepscan Presto BV (Lelystad, the
Netherlands). Due to dissolving problems, peptide IDO330−350
was omitted and only 58 peptides were included in the
immunization protocol (Table 2). Peptides were dissolved to a
concentration of 5mM in milliQ water, N-methyl-2-pyrrolidone
or 3% ammonia water in accordance with the supplier’s
recommendations, for further details see Supplementary Table 1.
Immunizations
Based on their SLA profile 12 animals (12 weeks old) were divided
in four groups each containing three pigs, hence maximizing
the MHC class I allelic coverage in each group. The animals
were primed at day 0 and boosted at day 19 with the full
20mer overlapping peptide library in combination with either
an adjuvant system or PBS. Each pig received 50µg for priming
and 25µg for boosting of each peptide with the exception of
certain peptides (Supplementary Table 1). The CAF09 adjuvant
(Korsholm et al., 2014) was a generous gift from Dennis
Christensen at the State Serum Institute, Copenhagen, Denmark
and vaccine doses for this group of animals were formulated
by gentle mixing of 1ml peptide library diluted in 10mM
Tris buffer with 1ml CAF09. A porcine/human modification of
CASAC (Wells et al., 2008) was prepared with the MegaCD40L R©
[1µg recombinant human CD154 and 2µg CD154 enhancer
(Enzo Life Sciences, NY, U.S.)], 500µg CpG ODN2007 (ODN
2007 Class B CpG oligonucleotide—bovine/porcine TLR9 ligand,
InvivoGen, CA, U.S.) and 1µg recombinant porcine IFN-γ
(R&D Systems, UK) all formulated in PBS and mixed with
peptides in a total volume of 1ml followed by gentle mixing
with 1ml of Sigma adjuvant (Sigma Adjuvant System, Sigma
Aldrich, Missouri, U.S.). Montanide ISA 51VG (Seppic, Puteaux,
France) vaccines were prepared by thorough mixing of 1ml
peptide library formulated in PBS and 1ml adjuvant through an
i-connector according to manufacturer’s instructions. Finally, a
vaccine formulated in PBS was produced with suspension of the
peptide library in PBS only. All vaccines were formulated in a
total volume of 2ml and administered subcutaneously into the
flank except for ISA 51 which was administered intramuscularly.
Priming and boosting were both administered into the left side
of the animals. Pigs were monitored for 5 days following priming
and boosting, and all animals remained healthy following both
injections.
9-11mer peptide Library for Immune Monitoring
Porcine IDO and RhoC aa sequences were obtained from the
Uniprot database (http://www.uniprot.org/uniprot/F6K2E8 and
http://www.uniprot.org/uniprot/F2Z5K4). Using PSCPL (Stryhn
et al., 1996) and the NetMHCcons1.1 server (Karosiene et al.,
2012) we identified 198 9-11mer peptides predicted to bind
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to at least one of the five in-house SLAs (SLA-1∗04:01, SLA-
1∗07:02, SLA-2∗04:01, SLA-2∗05:02, and SLA-3∗04:01) with a
rank score ≤ 2 % by at least one of the prediction methods.
These were synthesized via Fmoc-based chemistry and purchased
from Pepscan Presto BV (Lelystad, the Netherlands). For further
information see Supplementary Table 2. These peptides were
referred to as IDO1-IDO136 and RhoC1-RhoC62.
Test of Peptide-MHC Complex Stability
The stability of the selected 198 peptides in complex with
relevant SLA class I molecules and β2m was determined using
a scintillation proximity assay (SPA), as previously described
(Harndahl et al., 2011). Briefly, biotinylated recombinant MHC
class I heavy chains were attached to a streptavidin-coated
scintillation microplate together with iodinated (125I) β2m and
candidate peptide resulting in a scintillation signal, which was
consecutively measured every 40min by a scintillation plate
counter. The duration of this signal is directly correlated to
the stability of the peptide-MHC class I-β2m complex under
dissociating conditions and in the presence of excess unlabeled
β2m (Harndahl et al., 2011). Peptides with a half-life≥ 0.5 h were
selected as stable binders.
In vitro Peptide Stimulation of Porcine PBMCs
In a 96 well plate, 2×105 PBMCs/well were individually cultured
with 5µg/ml of each of the 80 peptides previously found to
form a total of 89 stable complexes with SLA class I heavy chain
and β2m. Cells co-cultured with Staphylococcal Enterotoxin
B (SEB) (1µg/ml) and media alone (RPMI 1640 (Gibco, Life
Technologies) supplemented with 10 % fetal calf serum) were
used as positive and negative controls, respectively. Cells were
cultured for 67.5–70.0 h and the supernatant was harvested,
frozen at −20◦C and subsequently analyzed for IFN-γ release by
an ELISA method.
IFN-γ Release Assay
Quantification of IFN-γ in the supernatant from cells stimulated
with 9-11mer peptides was carried out in a monoclonal ELISA
as previously described (Riber et al., 2011) except that the plates
were developed for 1–30min with tetramethylbenzidine (Kem-
En-Tec, Taastrup, Denmark) at RT. The absorbance at 450 nm
was determined using a microplate reader (Thermo Scientific)
and corrected for unspecific background by subtraction of
the signal at 650 nm. The detection limit was established
as 8.8 pg/ml and all measurements below this limit was
set at 8.8 pg/ml for further calculations. A vaccine-induced
response was defined as the increase from pre- to post-
vaccination after subtraction of the background IFN-γ from
media control cultures without added peptides. Samples from
three pigs (numbers 2033, 2045, and 2107) were excluded
from the analysis as negative control media cultures had high
non-specific background with IFN-γ levels above 20 pg/ml.
All positive control SEB cultures were above the 70 pg/ml
cut-off.
Statistics
Due to the low number of animals, statistical analyses between
different adjuvants are not meaningful and no statistical analyses
to prove significant differences were attempted.
Results
Previous studies have confirmed the involvement of CD8+ T
cells in anti-cancer immune reactivity (Klebanoff et al., 2005;
Sørensen et al., 2011b; Andersen, 2012; Joyce and Fearon,
2015; Rosenberg and Restifo, 2015) and anti-cancer vaccines
are generally administered with the aim of enhancing this
antigen- specific T-cell reactivity. To establish the pig as a
large animal model for human cancer vaccine development, we
constructed a monitoring platform for vaccine-induced T-cell
reactivity. First, candidate pigs were blood sampled and SLA-
typed in order to choose animals holding the relevant SLA
class I molecules (Figure 1). Second, identification of proteins
relevant for vaccination and prediction of candidate CD8+ T
cell epitopes from the full protein sequence were carried out.
The in vitro stability of the candidate T cell epitopes in complex
with relevant SLA class I molecule was then examined. Pigs were
immunized with 20mer overlapping peptides and blood sampled
at various time points pre- and post-immunization in order to
monitor the T-cell reactivity ex vivo (Figure 1). To increase the
knowledge obtained from this study, we stratified the pigs in
four groups based on their SLA-profile and immunized each
group with peptides in combination with an adjuvant system
or PBS.
FIGURE 1 | Overview of the immunization strategy. Prior to initiation of the vaccine trial, candidate pigs were blood sampled and SLA-typed in order to select
animals holding one or more of the following SLA alleles: SLA-1*04:01, SLA-1*07:02, SLA-2*04:01, SLA-2*05:02, and SLA-3*04:01. Pigs were then purchased and
blood sampled at day −2 to determine the background level of IFN-γ. At day 0, pigs were primed with 58 20mer overlapping peptides in combination with either
CAF09, CASAC, ISA 51VG or PBS. Blood samples were obtained at day 12, and all pigs were then boosted with another round of immunization at day 19. Blood
samples were obtained three times following boost namely at day 33, 40, and 54.
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SLA Class I Typing
We obtained blood from 24 animals and probed them for
the presence of SLA-1∗04:01, SLA-2∗04:01, SLA-1∗07:02, SLA-
2∗05:02, and SLA-3∗04:01 by Sanger sequencing (Table 1 and
data not shown) corresponding to our in-house recombinant
SLA library. Twelve pigs were positive for at least one of
the desired alleles and further NGS-based SLA-typing, which
also included expression analysis on RNA samples from these
animals, confirmed part of these along with the identification of
a few more expressed SLA molecules (Table 1). SLA-3∗04:01 was
found in nine of the pigs (75%) and seven pigs (58%) showed
expression of SLA-1∗04:01 (Table 1). SLA-1∗07:02 was found
in 50% of the animals, whereas SLA-2∗05:02 and SLA-2∗04:01
were found in only one (8%) and none of the pigs, respectively
(Table 1).
Analysis of Peptide-MHC Class I Binding Stability
In order to determine peptides capable of forming stable (t1/2 ≥
0.5 h) complexes with the relevant SLA amongst the 198 peptides,
the half-life of the peptide-MHC class I binding was determined
for each of the 244 predicted peptide-SLA complexes using SPA
analysis. For the widely distributed SLA-1∗04:01, a total of 12
IDO and RhoC-derived peptides formed stable complexes with
this SLA molecule (Figure 2A), and especially IDO122 showed
very high binding stability (t1/2 = 30.2 h, Figure 2B). Also, 26
peptides formed stable complexes with the other well-distributed
SLA-type amongst the pigs, namely SLA-1∗07:02 (Figure 2A).
Here, especially IDO21 (t1/2 = 10.1 h) and IDO88 (t1/2 =
24.0 h) were found to form highly stable complexes (Figure 2B).
Strikingly, only five peptides were found to form stable complexes
with SLA-3∗04:01 in the SPA analysis (Figure 2A), and IDO105
was the only peptide being able to form a complex with a
half-life longer than 1 h with this SLA molecule (t1/2 = 14.7 h)
TABLE 1 | SLA-profile of pigs included in the immunization trial.
Adjuvant Pig SLA-1*04:01 SLA-1*07:02 SLA-2*05:02 SLA-3*04:01
CAF09 2107
2035
2038
CASAC 2034
2037
2042
ISA 51VG 2046
2041
2043
PBS 2033
2045
2040
SLA-typing of animals included in the immunization trial. Animals were blood sampled
and tested for the presence of SLA-1*04:01, SLA-1*07:02, SLA-2*04:01, SLA-2*05:02,
and SLA-3*04:01 at both the DNA andmRNA level. , determined by Sanger sequencing-
based SLA-typing; , determined by NGS-based SLA-typing and expression analysis; ,
determined by both methods. None of the animals were positive for SLA-2*04:01 hence
this molecule was left out of the table. The Sanger sequencing-based SLA-typing was
unsuccessful for SLA-1*04:01.
(Figure 2B). A total of 24 peptides were shown to form stable
complexes with SLA-2∗05:02 (Figure 2A) with IDO16 (t1/2 =
12.5 h) forming the most stable complex. IDO21 and IDO29
were both found to form stable complexes with SLA-2∗04:01
exhibiting half-lives of 23.8 and 33.6 h, respectively (Figure 2B),
and additional 20 peptides also formed stable complexes with
SLA-2∗04:01. To sum up, the SPA analysis revealed 89 stable
peptide-SLA complexes (80 different peptides) from the 244
predicted high-affinity complexes (198 different peptides), and
these were used in subsequent analyses of the CD8+ T-cell
reactivity.
IFN-γ Responses
To monitor the induction of specific T cell populations, co-
cultures with peptide and PBMCs obtained at different time
points prior to and after the immunizations were analyzed
for IFN-γ release after ∼70 h. From the vaccine-induced
responses, a biologically relevant IFN-γ response following
peptide co-culture was defined as a 2-fold increase (stimulation
index = 2) as compared to pre-immunization (day -2) and with
a concentration of 25 pg/ml or more as depicted by the threshold
lines (Figure 2). Three pigs were excluded from the analysis due
to high non-specific background. For each animal, the peptide
responses were divided into two groups based on the measured
ability to form stable complexes with the SLA molecules found
in the SPA analysis (Table 1, Figure 2). In general, we found
responses in all pigs to both stable and non-stable binders
(Figure 3, Table 2, Supplementary Table 2). Despite similar SLA
profiles the pigs did not respond to the same peptides (Table 2).
When comparing the total number of responses of all animals
per adjuvant group, CASAC was shown to be slightly superior
especially at day 12 after the first immunization; however in
general the adjuvant systems performed similarly (Figure 4A).
Comparison of the average IFN-γ production (total amount of
IFN-γ divided by total number of responses) also revealed that
the adjuvants induced a similar level of this cytokine (Figure 4B).
Since the stability obtained in the SPA analysis has been used as
a determinant for selecting the ligands most likely to be CD8+
T cell epitopes, comparisons of the peptide-MHC class I half-
lives and IFN-γ production (Figure 4C) as well as stimulation
index (Figure 4D) were carried out. Surprisingly, no significant
correlations could be drawn from this analysis. More data points
are needed, especially for complexes with long half-lives, to fully
determine this, but our findings apparently do not support the
idea of stably binding peptides being more immunogenic as
shown by Harndahl et al. (2012). It should be noted, though, that
this study was performed with viral T cell epitopes. As shown
in Supplementary Table 2 we find responses against the vast
majority of stably binding peptides, however, for a significant
part of these there was a mismatch between the predicted SLA
restriction and the observed responses.
Discussion
To measure antigen-specific CD8+ T cell responses, knowledge
of the MHC class I alleles present in each individual is necessary.
SLA-3∗04:01 was found to be the most widely distributed of
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FIGURE 2 | Peptide-MHC class I binding stability as determined by SPA analysis. Stability of the predicted peptides in the 9-11mer peptide library with
relevant SLA molecules measured by the Scintillation Proximity Assay. (A) SPA-determined half-life of peptides predicted as binders for each SLA molecule. (B)
Individual peptides with SPA-determined half-life ≥ 0.5 h (stably binding) for each SLA molecule. Peptides derived from IDO and RhoC are shown in circles and
diamonds, respectively.
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FIGURE 3 | IFN-γ responses to the stable binders in the 9-11mer peptide library. PBMCs purified from immunized pigs at day −2, 12, 33, 40, and 54 were
stimulated with 80 peptides found to be stably binding to one or more of SLA-1*04:01, SLA-1*07:02, SLA-2*04:01, SLA-2*05:02, and SLA-3*04:01. A biological
(Continued)
Frontiers in Genetics | www.frontiersin.org 7 September 2015 | Volume 6 | Article 286
Overgaard et al. Pig model for cancer immunization
FIGURE 3 | Continued
relevant vaccine-induced response was defined as a 2-fold increase as compared to day −2 (dashed line, x-axis) and a concentration of IFN-γ equaling at least
25 pg/ml (dashed line, y-axis). For each animal, peptides were divided into two groups: stable (filled circles) and non-stable (open circles) referring to the binding
stability of a given peptide correlated with the SLA-profile of each pig. Responses occurring repeatedly in individual animals are highlighted by peptide name with
stably binding peptides being underlined. Animals with no responses at any time point, and time points for included animals with data not fulfilling the quality
parameters were left out of the analyses.
TABLE 2 | IFN-γ responses following co-culture with the 9-11mer peptide library.
SLA
molecule
Pig Adjuvant Total number of responses Stable binders
Day 12 Day 33 Day 40 Day 54 Day 12 Day 33 Day 40 Day 54
1
*0
4
:0
1
3
*0
4
:0
1
2034 CASAC 11 3 1 0 3(27.2%) 1(33.3%) 1(100.0%) –
2043 ISA 51VG 2 0 0 0 0(0.0%) – – –
1
*0
7
:0
2 2038 CAF09 2 1 0 1 0(0.0%) 0(0.0%) – 1(100.0%)
2042 CASAC 31 – 6 6 9(29.0%) – 3(50.0%) 3(50.0%)
2040 PBS – 0 – 9 – – – 3(33.3%)
1
*0
4
:0
1
1
*0
7
:0
2
3
*0
4
:0
1
2035 CAF09 4 2 0 3 1(25%) 1(50.0%) – 2(66.6%)
2046 ISA 51VG 1 3 0 0 1(100.0%) 1(33.3%) – –
1
*0
4
:0
1
2
*0
5
:0
2
3
*0
4
:0
1
2041 ISA 51VG – – 2 6 – – 0(0.0%) 2(33.3%)
Summarized responses from PBMCs co-cultured with the 9-11mer peptide library. Pigs are divided into four groups based on their SLA-profile. Adjuvant indicates immunization strategy,
i.e., CAF09, CASAC, ISA 51VG, or PBS injected animals. The total number of responses at day 12, 33, 40, and 54 are shown (column 4–7) as well as the number of responses generated
from co-culture with a peptide shown to stably bind the given SLA molecule (column 8–11). The percentage of responses generated from these stable binders is shown in brackets
for each time point. Animals with no responses at any time point are left out of the analysis. “–“ indicates that the quality control thresholds of the assay were not fulfilled and therefore
these data were left out of the analyses.
the five in-house MHC class I alleles; however the SLA-3∗04:01
molecule has previously been shown to be unstable, most likely
due to the presence of only one anchor position (Pedersen
et al. manuscript in preparation), and NGS analysis revealed a
significantly lower SLA-3∗04:01 expression level compared to the
expression of the SLA-1 and SLA-2 molecules (data not shown).
The pigs were divided into the adjuvant groups based on their
SLA-profile to stratify the study asmuch as possible and provide a
similar possibility of measuring antigen-specific T-cell responses
in all adjuvant groups.
To identify MHC class I ligands, we predicted binders (9-
11mer peptides) from the full length sequences of IDO and
RhoC to SLA-1∗04:01, SLA-1∗07:02, SLA-2∗04:01, SLA-2∗05:02,
and SLA-3∗04:01 by the combined use of NetMHCcons and
PSCPL. We selected peptides in the upper 2 % rank by either
of the methods. This ranking is a measure of the possibility
that a random peptide would be a better binder to the relevant
MHC complex. The resulting 136 and 62 predicted binders from
IDO and RhoC, respectively, were purchased and investigated
further (Supplementary Table 1). Some of the peptides ranked
≤2 % on more than one allele. The immunogenicity of a peptide
has previously been linked to the affinity of its binding to
MHC class I (Sette et al., 1994). However, it has recently been
suggested that the stability of the peptide-MHC class I binding
is a more accurate measure of the peptide’s immunogenicity
(Harndahl et al., 2012). Along with this note, the NetMHCstab
server has recently been established (Jørgensen et al., 2014), but
unfortunately this predictor does so far only work for a few
humanMHC class I molecules. Importantly, it has not previously
been possible to measure the peptide-MHC class I stability in a
high-throughput manner; however after development of the SPA
analysis, an essentially label-free stability screening approach is
now possible (Harndahl et al., 2011).
Vaccine efficacy can be determined in various ways, and
a typical approach to evaluate Th1-inducing adjuvant systems
is to measure the IFN-γ production. Importantly, the level of
secreted IFN-γ has been used to evaluate the efficacy of the only
FDA-approved therapeutic anti-cancer vaccine, PROVENGE R©
(sipuleucel-T), in a peptide-immunization study in mice (Saif
et al., 2014). Several cell types have the ability to produce
IFN-γ including Natural Killer T cells, Natural Killer cells,
CD4+ and CD8+ T cells amongst others. Here, in vitro peptide
co-culture of PBMCs purified pre- or post-immunization was
done with 9-11mer peptides. Therefore the IFN-γ production
observed following this co-culture is expected to originate from
CD8+ T cells encountering antigen-presenting cells presenting
peptides in the context of MHC class I. Since all animals
were found to respond to both stable and non-stable peptides
as determined by the SPA analysis, it could be indicative of
peptides with lower half-life than 0.5 h also having immunogenic
potential. Surprisingly, the animals generally did not respond
consistently to the same peptides over time. This might however
partly be due to blood sampling only showing a snapshot
of what is circulating in the blood stream. Also, most pigs,
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FIGURE 4 | Comparison of the adjuvant systems used in the immunization trial. The three Th1-inducing adjuvants CAF09, CASAC, and ISA 51VG were
compared on the basis of their ability to generate responses (A) and the total amount of peptide-specific IFN-γ produced from the culture (B) at the various time
points following immunization. For peptides found to be stably binding to MHC class I in the SPA analysis, half-life of the peptide-MHC class I complex was correlated
to the amount of IFN-γ (C) and the stimulation index (D).
like humans, have three MHC class I gene loci constitutively
expressed although duplication of the SLA-1 allele has been
observed in a fraction of animals (Lunney et al., 2004). Therefore,
most pigs express up to six different MHC class I molecules. We
have selectively tested for the five SLAs in our in-house library;
however the majority of the animals are expected to express
additional SLA molecules and we most likely do not know their
full SLA-profile. The additional SLA class I molecules might also
bind certain peptides in the 9-11mer library, which could account
for some of the responses to peptides not shown to bind stably to
our in-house SLA molecules.
In the majority of the animals, especially pigs 2034,
2035, 2040, and 2042, there seemed to be a correlation
between the stimulation index (as compared to day −2,
pre-immunization) and the amount of peptide-specific IFN-
γ produced. Unfortunately we had to exclude three pigs, two
from the PBS and one from the CAF09 group, from these
analyses due to high non-specific background. Recruitment
of pigs from a background of higher sanitation status could
provide a cleaner response window for future studies. The
animal receiving peptides formulated in PBS only also showed
responses to IDO and RhoC at day 54 post-immunization;
however naturally occurring CTL responses to endogenous
cancer antigens, among them IDO, have been frequently
observed in healthy humans as well (Visseren et al., 1995; Jäger
et al., 2001; Sørensen et al., 2011a; Frøsig et al., 2015). Further
of notice, two of the previous peptide vaccine human trials
with the most convincing clinical data used the granulocyte-
macrophage colony stimulating factor as the only adjuvant
(Inderberg-Suso et al., 2012; Walter et al., 2012). This cytokine
functions as a growth factor and does not stimulate immunity
directly as more common adjuvants do. Still, however, it seems
the identification of an optimal adjuvant system will be highly
beneficial.
Following immunization we found responses in most animals
and for most time points; albeit the secreted amount of IFN-
γ was fairly low, and the response magnitude can possibly be
enhanced by further optimizing the immunization protocol.
The generation of only a few specific T cells could, however,
be enough to induce epitope spreading generating mutation
antigen-specific T cells of higher avidity in a human cancer
setting. The frequency of specific T cell populations measured in
previous peptide vaccination studies in human cancer patients
have also generally been low (Pollack et al., 2014; Køllgaard
et al., 2015). This is probably due to the endogenous origin of
the targets, but nonetheless, in some of these studies a clear
clinical effect has been obtained. This was the situation in the
IDO peptide immunization trial (Iversen et al., 2014) where
47 % of the treated patients developed a long-lasting partial
response or stable disease, defined as 8.5 months compared to
the expected 6–7 months of progression-free survival in this
patient group. In addition, treated patients had significantly
longer overall survival than a cohort of patients of similar
shape not treated with the vaccine. Immunological activity was
found ex vivo in this trial, but at quite low frequencies. In
contrast, high-frequency immune responses are often found
in cancer immunization studies using murine models (Wei
et al., 2015) as exemplified in the study by Zhao et al. (2012),
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where more than 1000 pg/ml IFN-γ was secreted for most
peptides tested after two immunizations and only 48 h of peptide
stimulation ex vivo. For comparison, the maximum level of
secreted IFN-γ observed in our trial was 280 pg/ml IFN-γ
(pig 2042, day 12, peptide IDO15, Figure 3) following 72 h of
stimulation.
Here, we included three different Th1-inducing adjuvants,
namely CAF09, CASAC, and ISA 51VG and immunized three
pigs with each along with a fourth group receiving peptides
in PBS only. The PBS group was included as a control for the
adjuvant efficacy. From this study, none of the adjuvants were
found to be superior as they were all capable of generating a
CTL response toward cancer antigens found to be important in
human disease. Thus, despite very convincing data from mouse
studies (Wells et al., 2008), this first porcine/human modification
of CASAC was not superior in the pig model. The inconsistent
response profile highlights, however, the importance of further
optimization of peptide immunization protocols. In this study
we set out to analyze the vaccine-induced immune reactivity
on fresh material. Since the SPA analysis resulted in a peptide
library of 80 stably binding peptides, a total of approximately
1000 stimulations and 2000 ELISA well analyses were carried out
for each time point to measure the secreted IFN-γ. Due to this
large screening setup, analyzing more cytokines in parallel was
not feasible. To confirm the induction of antigen-specific CD8+
T cells following an immunization protocol, MHC multimer
staining for flow cytometry analysis is usually performed in
humans and mice. Although we have developed porcine MHC
multimers and staining protocols (Pedersen et al., 2014a),
we are still in the process of developing a high-throughput
MHC multimer screening system for porcine cells. We believe
the pig model is highly appropriate to address questions
relating to optimal adjuvant composition and formulation,
peptide repertoire and dosing, as well as the route and number
of administrations for endogenous peptide immunizations.
Supplemented with the porcine immunological reagents,
including recombinant SLA class Imolecules and SLAmultimers,
we will further be able to characterize the immunological
response profile following different immunization protocols
and relate this to the immunological correlates of anti-cancer
protection.
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